SCHEMBL5167578

SCHEMBL5167578

COC(=O)c1cc(NCC(C)=O)c(C(F)(F)F)cc1NC(=O)Oc1ccc(Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 5/20 0.42
HPGD P15428 3/20 0.42
CYP1A2 P05177 2/20 0.42
GAA P10253 2/20 0.41
GLA P06280 1/20 0.41
ATM Q13315 1/20 0.41
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
HTT P42858 1/20 0.39
LMNA P02545 3/20 0.38
RAB9A P51151 2/20 0.37
MAPT P10636 2/20 0.37
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5167582 0.80 KDM4E (0.42) KDM4EALDH1A1HPGDCYP1A2GAA
SCHEMBL5168756 0.77 KDM4E (0.41) KDM4EALDH1A1HPGDCYP1A2GAA
SCHEMBL2388560 0.75 KDM4E (0.41) KDM4EALDH1A1HPGDCYP1A2GAA
SCHEMBL13500111 0.74 KDM4E (0.39) KDM4EALDH1A1HPGDCYP1A2GAA
SCHEMBL2388475 0.74 KDM4E (0.41) KDM4EALDH1A1HPGDCYP1A2GAA
SCHEMBL2389800 0.74 KDM4E (0.38) KDM4EALDH1A1HPGDCYP1A2GAA
SCHEMBL2387516 0.74 ABL1 (0.45) KDM4EALDH1A1HPGDCYP1A2
SCHEMBL5167297 0.73 CFTR (0.59) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL3784326 0.67 KDM4E (0.62) KDM4EALDH1A1HPGDCYP1A2GAA
SCHEMBL3780392 0.67 ALDH1A1 (0.74) KDM4EALDH1A1HPGDCYP1A2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299085-B2 Quinazoline derivatives NOVARTIS AG (CH) 2012-10-30 US disclosed
US-20070208018-A1 Quinazoline Derivatives NOVARTIS AG (CH) 2007-09-06 US disclosed
EP-1773788-A2 QUINAZOLINE DERIVATIVES NOVARTIS-PHARMA GMBH (AT) 2007-04-18 EP disclosed
WO-2006010591-A2 QUINAZOLINE DERIVATIVES NOVARTIS AG (CH) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208018-A1 Quinazoline Derivatives CYP3A5, CYP3A7, CYP3A4 KDM4E 1450/4885ALDH1A1 460/4885HPGD 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.